Pembrolizumab for Early Triple-Negative Breast Cancer


Schmid P., Cortes J. , Pusztai L., McArthur H., Kuemmel S., Bergh J., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.382, ss.810-821, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 382 Konu: 9
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1056/nejmoa1910549
  • Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
  • Sayfa Sayıları: ss.810-821

Özet

Background Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear.